Nano Drug Interventional Therapy Using Digital Subtraction Angiography（DSA） for Lung Carcinoma

Nano Drug Interventional Therapy Using Digital Subtraction Angiography（DSA） for Lung Carcinoma：Clinical Trial

Status

Completed

Phases

Phase 1Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02449122

Enrollment

Registered

2015-05-20

Start date

2015-05-31

Completion date

2016-02-29

Last updated

2016-02-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung Cancer

Keywords

Lung Cancer, Nano drug

Brief summary

The purpose of this study is to evaluate the safety and efficacy of nano drug interventional therapy using digital subtraction angiography（DSA） for lung cancer. The nano drug is made by mixing Gemzar® with Compound Glycyrrhizin Injection.

Detailed description

By enrolling patients with lung cancer adapted to enrolled criteria, this study will document for the first time the safety and the short and long term efficacy of nano drug interventional therapy using digital subtraction angiography（DSA）for lung cancer. The nano drug is made by mixing Gemzar® with Compound Glycyrrhizin Injection. The nano drug's size is detected by laser diffraction particle size analyzer.

Interventions

PROCEDUREinterventional therapy

Lung cancer patients received drug interventional therapy using the digital subtraction angiography（DSA.）

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 80 Years

Healthy volunteers

Inclusion criteria

1. Age:18-80 2. Karnofsky performance status \>60 3. Diagnosis of lung cancer based on histology or the current accepted radiological measures. 4. Classification tumor,nodes,metastasis-classification(TNM) stage: Ⅱ,Ⅲ,Ⅳ 5. Will receive interventional therapy 6. Life expectancy: Greater than 3 months 7. Patients' routine blood test, liver function and kidney function have no obvious abnormalities 8. Ability to understand the study protocol and a willingness to sign a written informed consent document

Exclusion criteria

1. Patients with other primary tumor except lung cancer 2. History of coagulation disorders or anemia

Design outcomes

Primary

Measure	Time frame
Number of participants with Adverse events	1 year

Secondary

Measure	Time frame
Percentage of lesions that show no sign of recurrence 12 months after interventional therapy	1 year
Progress free disease (PFS)	1 year
Overall survival (OS)	1 year

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026